Journal of Substance Abuse Treatment

Papers
(The TQCC of Journal of Substance Abuse Treatment is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
C2: editorial board123
JSAT call for papers for special issue: Stimulant use disorder85
Barriers to accessing treatment for substance use after inpatient managed withdrawal (Detox): A qualitative study85
Community perspectives on supervised consumption sites: Insights from four U.S. counties deeply affected by opioids75
Substance use disorders among older populations: What role do race and ethnicity play in treatment and completion?60
The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder57
Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings52
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail51
A qualitative study of service engagement and unmet needs among unstably housed people who inject drugs in Massachusetts50
Augmenting substance use treatment in the drug court: A pilot randomized trial of peer recovery support50
The new services that opioid treatment programs have adopted in response to COVID-1949
Integrating substance use care into primary care for adolescents and young adults: Lessons learned49
C2: editorial board48
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders45
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data44
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services43
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail42
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up41
Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis39
Serial mediation analysis of treatment-specific processes in two contrasting alcohol treatments38
Education and careers were our way out36
What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings35
C2: editorial board33
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration31
Al-Anon Intensive Referral (AIR): A qualitative formative evaluation for implementation31
What is the relapse risk during treatment? Survivor analysis of single and multiple relapse events in inpatients with alcohol use disorder as part of an observational study31
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)31
Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam30
Association between industry sponsorship and author conflicts of interest with outcomes of systematic reviews and meta-analyses of interventions for opioid use disorder30
Emergency department interventions for opioid use disorder: A synthesis of emerging models30
A randomized clinical trial evaluating the impact of counselor training and patient feedback on substance use disorder patients' sexual risk behavior29
Using machine learning to identify predictors of imminent drinking and create tailored messages for at-risk drinkers experiencing homelessness28
Targeting women veteran's stress-induced drinking with cognitive reappraisal: Mechanisms and moderators of change28
Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults28
Can nicotine replacement therapy be personalized? A statistical learning analysis28
Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform28
Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers26
Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting26
Adapting methadone inductions to the fentanyl era25
Facing the future of substance use disorders treatment in Vietnam – A case study for international development and cooperation25
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)24
The impact of social network dynamics on engagement in drug use reduction programs among men and women who use drugs24
Improving geographic access to methadone clinics24
Using machine learning to examine predictors of treatment goal change among individuals seeking treatment for alcohol use disorder24
Tobacco smoking and nicotine dependence among patients with respiratory diseases in Vietnam: Status and correlated factors24
Addressing adolescent substance use in an urban pediatric federally qualified health center24
Connecting and disconnecting: Experiences of people with opioid use disorder in intensive outpatient treatment24
Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden23
The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives23
A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment23
Mobile-based brief interventions targeting cannabis-impaired driving among youth: A Delphi study23
National trends in substance use treatment admissions for opioid use disorder among adults experiencing homelessness23
Drug court utilization of medications for opioid use disorder in high opioid mortality communities22
Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder22
Latent class analysis of self-reported substance use during incarceration: Gender differences and associations with emotional distress and aggressiveness22
An exploration of thriving over time in recovery22
C2: editorial board21
Scoping review of interventions to link individuals to substance use services at discharge from jail20
Adapting and scaling a single site DEA X-waiver training program to a statewide initiative: Implementing GetWaiveredTX20
Recovering from substance use disorders during the early months of the COVID-19 pandemic: A mixed-methods longitudinal study of women in Kansas City20
Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon20
Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes20
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs19
Associations between patient experience and clinical outcomes in substance use disorder clinics: Findings from the veterans outcomes assessment survey19
Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study19
Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): A national qualitative study19
Corrigendum to “Feasibility and acceptability of mindful recovery opioid use care continuum (M-ROCC): A concurrent mixed methods study” [Journal of Substance Abuse Treatment 130 (2021) 108415]19
Associations between prescription and illicit stimulant and opioid use in the United States, 2015–202019
Contingency management for treatment attendance: A meta-analysis19
The impact of COVID-19 on health care professionals who are exposed to drug-related deaths while supporting clients experiencing addiction19
Patterns of enrollment in a New Orleans women's substance use rehabilitation center19
Emotion dysregulation and hazardous drinking in relation to suicidal ideation among Spanish-speaking Latinx daily-smokers19
Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals19
Recidivism prevention for impaired driving: Longitudinal 5-year outcomes from Quebec's severity-based intervention assignment program19
C2: editorial board19
Where did the specialty behavioral health workforce grow between 2011 and 2019? Evidence from census data18
SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups18
Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine18
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, he18
Racial disparities in linkage to care among patients with substance use disorders18
Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder17
Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use17
C2: editorial board17
Value of family involvement in substance use disorder treatment: Aligning clinical and financing priorities17
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-1917
TOC (update)17
Alcohol and drug use among bartenders: An at risk population?17
Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder17
C2: editorial board17
Mobile low-threshold buprenorphine integrated with infectious disease services16
Follow-up after ED visits for opioid use disorder: Do they reduce future overdoses?16
The effect of nicotine dependence and withdrawal symptoms on use of nicotine replacement therapy: Secondary analysis of a randomized controlled trial in primary care16
Mobile methadone medication units: A brief history, scoping review and research opportunity16
TOC (update)16
Predictive validity of the New York State Level of Care for Alcohol and Drug Treatment Referral (LOCADTR) for continuous engagement in treatment among individuals recommended for outpatient care16
Developing a cascade of care for opioid use disorder among individuals in jail16
TOC (update)16
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study16
Prescribing buprenorphine for opioid use disorder in primary care: A survey of French general practitioners in the Sentinelles network15
Reducing Opioid Mortality in Illinois (ROMI): A case management/peer recovery coaching critical time intervention clinical trial protocol15
Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world15
Alcohol use disorder and treatment receipt among individuals aged 50 years and older: Other substance use and psychiatric correlates15
Patient-centered primary care and receipt of evidence-based alcohol-related care in the national Veterans Health Administration15
How emergency department visits for substance use disorders have evolved during the early COVID-19 pandemic15
The short-term effectiveness of real-time video counselling on smoking cessation among residents in rural and remote areas: An interim analysis of a randomised trial15
C2: editorial board15
Parental status and characteristics of women in substance use treatment services: Analysis of electronic patient records15
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder15
Client attitudes toward virtual treatment court15
Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder15
Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences15
0.064555883407593